[1] Amornmarn R, Bui MM. Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy[J]. Ann Clin Labo Sci, 2000, 30(1):33-40.
[2] Kurihara T, Brough DE, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antige[J]. Journal Clin Invest,2000, 106(6):763-771.
[3] Indraccolo S, Cola E, Rosato A, et al. Differential effects of angiostatin endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells[J]. Gene Therapy, 2002, 9(13):867-878.
[4] Lichtor T, Moser R, Cohen EP. Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice[J]. J Neurosurg, 2001, 94(2):287-292.
[5] Obermiller PS, Tait DL, Holt JT. Gene therapy for carcinoma of the breast:Therapeutic genetic correction strategies[J]. Breast Cancer Res, 2000, 2(1):28-31.
[6] Lesoom, Wood LA, Kim WH, et al. Systemic gene therapy with p53 reduces growth and metastastase so famalignant human breast cancer in nude mice[J]. Hum Gene Ther,1995, 6(4):39-52.
[7] Wang SC, Zhang L, Hortobagyi GN, et al. Targeting HER2:recent developments and future directions for breast cancer patients[J]. Semin Oncol, 2001, 28(6 Supp118):21-29.
[8] Springer CJ, Niculescu-Duvazl I. Prodrug activating systems in suicide gene theraphy[J]. J Clin Inves, 2000, 105(9):1161-1167.
[9] Morimoto J, Otsuki Y. Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation[J]. Cancer Gene Ther, 2002, 9(1):16-27.
[10] Grignet-Debrus C, Cool V, Baudson N, et al. The role of cellular-and prodrug-associated factors in the bystander effect induced by the varicella zoster and herpes simplex viral thymidine kinases in suicide gene therapy[J]. Cancer Gene Ther, 2000, 7(11):1456-1468.
[11] Balzarini J, Ostrowski T, Goslinski T, et al. Pronounced cytostatic activity and bystander effect of a novel series of fluorescent tricyclic acyclovir and ganciclovir derivatives in herpes simplex virus thymidine kinase gene-transduced tumor cell lines[J]. Gene Ther, 2002, 9(17):1173-1182.
[12] Guha C, Guha U, Tribius S, et al. Antisence ATM gene therapy:as trategy to increase the radios ensitivity of human tumors[J]. Gene Ther, 2000, 7(10):852-858.
[13] Majumdar AS, Zolotorev A, Samuel S, et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model[J]. Cancer Gene Ther, 2000,7(7):1086-1099.
[14] Braiden V, Ohtsuru A, Kawashita Y, et al. Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter[J].Hum Gene Ther, 2000, 11(18):2453-2463.
[15] Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirus-mediated gene transfer[J]. Cur Gene Ther, 2001,1(1):101-122.
[16] Vlachaki MT, Chhikara M, Aguilar L, et al. Enhanced therapeutic effect of multiple injections of HSV-TK+GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model[J]. Int J Radiat Oncol Biol Phys,2001, 51(4):1008-1017.
[17] Larson SM, Tjuvajev J, Biasberg R. Triumph qver mischance:a role for nuclear medicine in gene theraphy[J]. J Nucl Med, 1997, 38:1230-1233.
[18] Mairs R J, Cunningham SH, Boyd M, et al. Application sof gene transfer to targeted radiotherapy[J]. Curr Pharm Des,2000, 6(14):1419-1432.
[19] Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy[J]. Cancer Res, 2000, 60(13):3484-3492.
[20] Larnmering G, Hewit TH. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization[J]. J Nat Cancer Inst, 2001, 93(12):921-929.
[21] Germann C, Shields AF, Griersion JR, et al. 5 Fluoro 1(2,deoxy 2, fluorobeta Dribofuranosyl) uraciil trapping in morris hepatoma cell sex pressing the herpes simple the herpes simplex virus thymid ine kinase gene[J]. J Nucl Med,1998, 39(8):1418-1423.